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ABSTRACT 
Background: Extended spectrum beta lactamase (ESBL) producing Enterobacteriaceae (ESBL-PE) 
are a group of bacteria that are resistant to a conventional therapy, in particular third generation 
cephalosporins, fluoroquinolones and penicillins. Currently, there are growing evidences indicating 
that drug resistant bacteria notably ESBL-PE is greatly implicated in immune-compromised groups 
namely individuals with HIV infection.  However, little is known about the burden of ESBL-PE in 
places where HIV infection is rampant.  
Objective: To assess the prevalence, antimicrobial resistance pattern of ESBL-PE among HIV/AIDS 
patients at the University of Gondar hospital, North-west Ethiopia. 
Method: A cross-sectional study was conducted among HIV/AIDS patients seeking ART service at 
the University of Gondar Hospital ART clinic from February-May, 2017. Pre-tested and structured 
questionnaire was used to collect data on socio-demographic and clinical related factors. Clean catch 
mid-stream urine samples were collected and cultured in line with standard procedures. The drug 
susceptibility testing was performed by Kirby Bauer disc diffusion method.  ESBL detection was 
performed using double disc synergy test and combined disc methods. Data entry and analysis was 
performed using SPSS version 20.  
Result: Among a total of 387 HIV/AIDS patients, 42 (10.9%) Enterobacteriaceae uropathogens were 
recovered. Of these isolates, nine (21.4%) were ESBL producers. The highest prevalence of ESBL 
production was noted in E.coli (44.4%) followed by K.pneumoniae (22.2%) and Enterobacter spp. 
(22.2%).  Higher drug resistance rates were observed among ESBL producing isolates compared to 
ESBL non producing isolates. The ESBL-PEs demonstrated no resistance to Nitrofurantoin, whereas 
high resistance rates were noted to Amox-clavulanic (100%), Ampicillin (95%), Cotrimoxazole 
(74%), cefotaxime (88.9%) and ceftazidime (88.9%). The overall prevalence of multidrug resistance 
of all isolates was 92.9% and all ESBL isolates were multidrug resistant 
Conclusion and Recommendation: Considerably, high prevalence of ESBL-PE was observed in 
HIV patients. E. coli and K. pneumonia were the most prevalent ESBL producers. All ESB-PE 
isolates were MDR for all tested antimicrobial agents. Antibiotic resistance rates in ESBL-PE isolates 
were significantly higher than other ESBL non producing isolates Therefore, antimicrobial 
stewardship programs needed to be promoted for rational use of drugs especially in the management 
of HIV/AIDS patients.   
Key words: Antimicrobial Susceptibility pattern, Extended Spectrum Beta lactamase (ESBL), 
Ethiopia, HIV.
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1. INTRODUCTION 
1.1. Background 
Enterobacteriaceae are groups of non-sporulating, facultative anaerobic Gram negative 
bacteria, and are natural inhabitants of human and animal intestine, but some of them like 
Salmonella spps., Shigella spps. and Yersinia spp are human intestinal pathogens (1–3). 
Besides, they are usually found in soil, environment and on plants (4,5). These includes 
Escherichia coli, Klebsiella spp., Proteus spp., Morganella spp., Providentia spp., 
Enterobacter spp., Serratia spp, salmonella spp., Shigella spp. and Yersinia spp. Especially, 
Escherichia coli, and Klebsiella spps. are the most implicated opportunistic pathogens, which 
frequently cause a variety of community and hospital acquired infections, including urinary 
tract infection (UTI), bacteremia, pneumonia, abdominal infections, meningitis, and wound 
infection, mainly in immuno-compromised population, notably in Human Immunodeficiency 
Virus (HIV) /AIDS patients (4).  
Serious bacterial infections have emerged as an important cause of morbidity and mortality 
in individuals with HIV with case-fatality rates of up to 32% in patients with CD4 count less 
than 200 cells/l (6,7). Peoples with HIV infection are more susceptible and increased rate of 
morbidity and mortality to bacterial infections because of defects in both cell-mediated and 
humeral immunity that leads for these patients to be exposed for multiple treatments. This 
multiple treatment finally facilitates for the emergence of drug resistant isolates via selective 
pressure as the survived strains are free to outnumber their population making the treatment 
ineffective. Moreover, many HIV patients are given primary cotrimoxazole prophylaxis that 
might increase the risk of antibiotic resistance in a variety of bacterial pathogens in high-risk 
population. As a result, management of bacterial infections in HIV patients is important for 
preventing further emergence of drug resistance (6–8). 
Enterobacteriaceae are important human pathogens while increasing number of antibiotic 
resistant strains are detected worldwide. The most commonly observed resistances were 
against beta-lactams, fluoroquinolones, aminoglycosides and recently polymyxins (3). 
Enterobacteriaceae can develop several mechanisms to avoid the inhibitory effect of 
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antibiotics thus, becoming resistant. Nowadays, multi-drug resistant strains emerged, 
possessing several resistant mechanisms against different antibiotic groups (3). 
Resistance mechanisms can be described in two ways: Intrinsic resistance mechanism 
whereby microorganisms naturally do not possess target sites or they naturally have low 
permeability for the drugs and acquired resistance mechanism whereby a naturally 
susceptible microorganism acquires resistance mechanisms through; production of 
hydrolyzing enzymes, mutation and post-transcriptional or post-translational modification in 
the targets, active efflux of the antimicrobial agent, overproduction of the targets and 
expression or suppression of a gene in vivo in contrast to the situation in vitro. Most 
importantly, resistance to beta-lactam antibiotics occurs by three mechanisms: failure of the 
beta-lactam to reach the penicillin-binding proteins (PBPs), low-affinity to the PBPs and 
inactivation of the drug by beta-lactamases. Among this,  beta-Lactamases are the 
commonest cause of bacterial resistance to beta-lactam antimicrobial agents which hydrolyze 
the beta lactam rings (9,10). 
Extended-spectrum beta-lactamases (ESBLs) are a plasmid mediated heterogeneous group of 
transferable beta lactamase enzymes that hydrolyze penicillins, first-, second-, and third-
generation cephalosporins, aztreonam and other antibiotics like aminoglycosides, 
fluoroquinolones, tetracyclines, chloramphenicol and sulfamethoxazoletrimetroprim but not 
cephamycins and carbapenems and also blocked in vitro by beta-lactamase inhibitors such as 
clavulanate, tazobactam and sulbactam (11–16). The first report of plasmid-encoded beta 
lactamases was published in 1983 in Germany. Later these enzymes were named extended-
spectrum beta-lactamases (9,17).  
Most ESBLs have evolved by point mutation of naïve TEM, SHV and recently CTX-M beta-
lactamases with amino acid replacement, resulting for more than  150 variants of ESBL 
enzymes (9,18–20). The most common ESBLs types recognized currently are TEM 
(Temoniera)-beta-lactamases, SHV (sulphydril variable)-beta-lactamases, and CTX-M 
(Cefotaximase-Munich) beta-lactamases. Each of these enzymes derives from its own 
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progenitor. Interestingly, SHVs are more prevalent in Europe; TEMs are dominantly present 
in the USA while the CTX-Ms are being increasingly detected worldwide (3). 
Extended spectrum beta lactamases producing Enterobacteriaceae (ESBL-PE) have spread 
widely and have become a major cause of nosocomial infections associated with high 
mortality rates, particularly in serious infections such as urinary tract infection (UTI). The 
widespread use of broad spectrum antibiotics which account for approximately 50% of global 
antibiotic consumption and, prolonged hospitalization, severe illnesses, co-morbidities like in 
case of HIV/AIDS, recent surgery, instrumentation, admission to an intensive care unit, 
combination of antibiotic therapy with a quinolone and empirical treatment without proper 
antibiotic susceptibility testing are the major causes for the development of multidrug 
resistant (MDR) infection with ESBL-PE (9,21–23). 
Majority of ESBL-PE associated infections are resistant to various antibiotics, leaving only 
limited compounds as a choice of therapy. Presently, carbapenems became the first line 
antimicrobials for the treatment of such infections (24). 
Proper infection control practices and barriers are essential to prevent spreading and 
outbreaks of ESBL producing bacteria. The reservoir for these bacteria seems to be the 
gastrointestinal tract of patients, oropharynx, colonized wounds and urine (25). Alternative 
reservoirs like contaminated hands and stethoscopes of healthcare providers are also 
important factors in spreading infection between patients (25). Essential infection control 
practices should include avoiding unnecessary use of invasive devices such as indwelling 
urinary catheters or IV lines, hand washing by hospital personnel, increased barrier 
precautions, and isolation of patients colonized or infected with ESBL producers (26). 
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1.2. Statement of the problem 
Infectious diseases had been the leading cause of death until the middle of the 20th century or 
until the introduction of novel antibiotics in clinical medicine (27). The introduction of 
antibacterial agents was immediately accompanied by the emergence of drug resistant 
organisms which adapted different mechanisms to counter the effect of the antibiotics 
(28,29). In the fight against the drug resistant strains of bacterial pathogens, few potent drugs, 
including the third generation cephalosporins have been discovered and have been in use for 
the treatment of various bacterial infections (30). However, the continual emergence of drug 
resistant pathogenic bacteria, including the more potent third generation cephalosporin drugs 
made a great impediment to the rapid prognosis of patients that has been a major clinical 
problem in the treatment of various infections caused by members of the Enterobacteriaceae 
(31). 
Infections caused by ESBL producing bacteria often involve immune-compromised patients 
(like in HIV patients), making it difficult to eradicate these organisms in high-risk wards, 
such as intensive care units (32,33). Extended spectrum beta lactamases strains have been 
associated with resistance to other non beta-lactam antibiotics like aminoglycosides and 
chloramphenicol. Another challenging property related to ESBL strains is that they might 
show a false sensitivity in vitro testing which leads to inappropriate antibiotic selection in 
infections caused by these organisms resulting for treatment failures, poor clinical outcomes, 
prolonged hospital stay, delayed initiation of appropriate antibacterial therapy, increased 
morbidity, mortality and health care costs   (34–37). 
In the past 2 decades, there has been an explosive increase in the prevalence of high-level 
resistance to beta-lactam antibiotics in members of Gram-negative Enterobacteriaceae  (35). 
The current increase in ESBL producing bacteria in patients at the time of hospital admission 
points towards a continent-wide rise, mainly in Escherichia coli, with great variations in the 
occurrence and distribution of different ESBLs among countries and even among different 
regions of a country (38). 
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The global prevalence of ESBL producing organisms is presently increasing from <1% to 
74% (39,40) that might be because of the global increasement of the prevalence of 
HIV/AIDS and other factors which contribute to immunosuppression. In the decade of the 
1990s, ESBL producing isolates raised from 6% to 9% in United States, 10% to 35%, Latin 
America, 5.5%  to 8%, Korea, 12 to 24, Thailand, 46% to 50% India (14,41–45) and a high 
prevalence of ESBL in Tanzania and South Africa which account 29% and 36.1% 
respectively (17,46). In Ethiopia, some local studies revealed that the magnitude of ESBL 
isolates are increasing from 38.4% to 52% (9,47). 
This upward trend of ESBL-PE especially in sub-Saharan Africa (SSA) counties might be 
due to poor hygiene, unreliable water supplies, civil conflicts, and increasing numbers of 
immunocompromised people, such as those with HIV/AIDS, which facilitate both the 
evolution and their rapid spread in the community of resistant pathogens through selective 
pressure (48).  
By the end of 2013,  66.7% of 6000 new global HIV infections each day, and 74% of 1.5 
million AIDS related deaths from the world accounted in sub-Saharan Africa countries (49).  
This increased prevalence of HIV/AIDS infections, especially in sub-Saharan African 
countries, including Ethiopia has predisposed populations to the excessive increase in the 
utilization of antibiotics to prevent and treat opportunistic infections since these patients are 
highly exposed for a number of and frequent infections which raise concerns over the 
looming emergence and spread of resistance to cheap and well-tolerated antibiotics (48). For 
instance, in a survey on E. coli in Kenya, 27% were ESBL of which 57.8% were MDR (50),  
Guinea-Bissau, 32.6% ESBL producing E. coli and nearly all isolates were multidrug 
resistant (51) , Cameroon, 16% E. coli showed ESBL production (52), Gabon, 45%  revealed 
ESBL carriage and most isolates were MDR strains (53). Due to limited capacity for disease 
detection and surveillance, the burden of illnesses due to treatable bacterial infections, their 
specific etiologies, and awareness of antibacterial resistance is less well established in most 
of SSA, and therefore, the ability to mitigate their consequences is significantly limited (48). 
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Studies have been conducted on the ESBL-PE strains in some part of Ethiopia like in Jimma 
(9), Harar (54), Addis Ababa (47) and Adama (31) on the prevalence of ESBL producing 
E.coli and K. pneumoniae that investigated for the existence and prevalence of ESBL 
producing isolates of E.coli and K.pneumoniae, but did not consider other 
Enterobacteriaceae species with ESBL producing isolates. Therefore, the present study was 
aimed to figure out the burden, antimicrobial resistance pattern of ESBL-PE isolates among 
HIV/AIDS patients. 
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1.3. Literature reviews 
1.3.1. Epidemiology of ESBL Producing Enterobacteriaceae  
The upward trend in the prevalence of pathogens producing ESBLs is of increasing clinical 
concern. Infections with these ESBL producing organisms continue to be associated with 
higher rates of mortality, morbidity and health care costs (55). The prevalence of ESBL 
producing bacterial pathogen varies from country to country and even locally within the 
same country (31,56). 
Low prevalence of ESBL-PE has been reported in studies conducted in the USA (8.6%), and 
UK (1%). Both studies have also indicated that E. coli and K. pneumoniae were the first and 
the second ESBL producing bacteria (57,58). Relatively, the high burden of ESBL-PE has 
been implicated in Asian countries, ranges from 22.9% to 69% (55,59–61). The most 
common ESBLPEs were K. pneumoniae (36 to 71.4%), E. coli (10.8% to 60%), and K. 
oxytoca (4 to 28.6%). E. coli that produce ESBL showed maximum susceptibility to 
imipenem (100%), followed by piperacillin-tazobactum (84%), amikacin (68%), gentamicin 
(9%), ciprofloxacin (9%) and amoxicillin-clavulanic acid (7%). Similarly, ESBL producing 
K. pneumoniae showed a very good susceptibility to imipenem (98%), followed by 
piperacillin-tazobactum (68%), amikacin (40%), gentamicin (15%), ciprofloxacin (15%) and 
amoxicillin-clavulanic acid (5%). 
Several studies have been undertaken in different settings of African region. A finding from 
Nigeria among HIV/AIDS patients revealed that 17.3% were positive for ESBL production, 
28.9% were from E. coli, 20.0% from K. pneumoniae, 15.6% from P. aeruginosa, 11.1% 
from Serratia marcescens, 6.7% from Salmonella spp., 11.1% from Proteus spp., 4.4% from 
Citrobacter spp. and 2.2% from Enterobacter spp. (62). Comparatively, high prevalence of 
ESBL-PE (49.3%) has been reported in Ghana. The prevalence within each species was the 
highest among Enterobacter cloacae, 75.0%, followed by K. pneumoniae, 61.5%, C. 
freundii, 50%, K. oxytoca, 45.0% and E. coli, 43% (63). Similarly a high prevalence of 
ESBL-PE (62 %) was reported in Uganda, Mulago Hospital. Escherichia coli was the most 
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isolated organism (53.9 %), followed by K. pneumoniae (28.7 %). A higher percentage of 
isolates were showing resistance to ceftazidime (73 %) compared to cefotaxime (57.5%) 
(64). Similar study in 3 main Burkinafaso hospitals has revealed that 58 % were identified as 
potential ESBLs-PE of which 67.5 % E. coli, 26 % K. pneumoniae, 4 % Enterobacter 
cloacae, 1 % Providencia stuartii, 0.5 % Enterobacter aerogenes, 0.5 % Citrobacter freundi 
and 0.5 % Morganella morgannii species (65).  
There are few studies conducted in Ethiopia on ESBL-PE. A finding from Adama Hospital, 
Ethiopia reported that 25% were ESBL producers from Enterobacteriaceae  isolates of which 
E. coli was the leading ESBL producer (28.57%) while Proteus species, Klebsiella species, 
E. cloacae and Citrobacter species accounted for 33.3%, 25%, 33.3% and 33.3% 
respectively (31). Similar study in Jimma University Specialized Hospital, South-West, 
Ethiopia has showed that 38.4% ESBL-PE of which 28.2% was E. coli and 70.4 % was K. 
pneumoniae (9). 
A high prevalence (52%) of gastrointestinal carriage rate of ESBL-PE was investigated in 
Tikur Anbesa Specialized Hospital of which, E. coli and K. pneumoniae accounted 68% and 
32%, respectively (47). It was also found that 33.3% of Klebsiella isolates were ESBL-PE 
from Klebsiella spp. isolates in clinical samples in a study conducted in four different 
hospitals of Harar region. Klebsiella spp. resistance pattern was found against 
cephalosporins: cefotaxime (39%), cefoxitin (39%), ceftazidime (40%), ceftriaxone (40%), 
cephalothin (42%), chloramphenicol (70%), gentamicin (61%) and trimethoprim-
sulphamethoxazole (65%). Multi-drug resistant isolates were more prevalent among the 
ESBLs producers (95%) than non-producers (53%) (54). 
Regarding with MDR patterns of Enterobacteriaceae isolates, different studies in the world 
has been depicting that the rate of multidrug resistance (MDR) is increasing. A study from 
different areas like USA and Nepal has shown the prevalence of 19.1% and 41.1% 
respectively (66,67). Additionally,  a high prevalence of MDR was reported from 
Mozambique (88.2%) among Enterobacteriaceae (68). 
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Moreover, very high prevalence of MDR was reported in different areas of Ethiopia in 
different times with a prevalence of 90.8% from Hawasa (69), 100% from Jimma (70), 
75.2% from Dessie (71), 92.2% from Bahir Dar (72); 87.4%  and 93.5% from Gondar 
(73,74) .  
1.3.2. Risk factors for ESBL producing Enterobacteriaceae infection 
Various studies have been conducted on epidemiology and risk factors associated with 
infections with ESBL producing bacteria. The most recognized risk factors for ESBL  
infections includes age, gender, prolonged hospital stay, surgical intervention, irrational 
antibiotic use, central venous catheterization, residence in a long-term care facility, chronic 
disease such as diabetics, HIV, and liver  disease (75,76). The link between previous 
hospitalization and ESBL infection was previously reported. For example, the prevalence of 
ESBL infection among hospital admitted patients was reported 45.9% in Turkey among 
children (77). More than that, a higher prevalence (50.5%) of ESBL infection was reported in 
Israel (78). 
Recent surgery, antibiotic use within the 30 days preceding the infection and presence of  
urinary catheter were significantly associated with an increased risk for infection with an 
ESBL-producing organism from a study conducted in Lebanon (79). Additionally, recent 
treatment in a foreign country, previous antibiotic therapy and Mechanical ventilation  
increased the risk of infections due to ESBL producing E. coli or K. pneumoniae in a study 
conducted in Switzerland (80). In a study from Barcelona also found that acquisition of 
resistant or potentially resistant microorganisms had a significantly lower CD4 cell count 
than those who did not acquire this microorganism in HIV-infected patient (81). 
Transfer of patients from another ICU, hospital admission in another country, surgery within 
the past year, prior neurologic disease, and prior administration of third generation 
cephalosporin (within 3–12 months before ICU admission) were found to be independent 
predictive factors of colonization by ESBL from  a study in France hospital ICU patients 
(82). Similarly, a study in Israel upon hospital admitted patients revealed that nursing home 
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residency, prior hospitalization, prior antibiotic treatment and prior ESBL carriage were  risk 
factors for ESBL infection (78). 
Previous use of antibiotics, urinary catheter, mechanical ventilation, previous hospitalization 
and nosocomial origin of infection were significant risk factors for acquiring ESBL infection 
from a study  conducted  in Saudi Arabia (83). A multinational survey conducted in Europe, 
Asia, and North America revealed that  recent antibiotic use, residence in a long term care 
facility, recent hospitalization, age >65 years, and male sex were the significantly associated 
risk factors (84). 
A study in  Ghana showed that distribution of ESBL producing isolates was compared across 
age groups, ESBL prevalence was significantly higher among isolates from patients at 
extremes of ages, specifically neonates (65.1%) and adult patients > 65 years of age (70.5%) 
(63). In Ethiopia, treatment with third generation cephalosporin was identified as a sole risk 
factor for acquisition of ESBL enzyme from a study in Jimma University specialized 
Hospital (9). 
1.4. Significance of the Study 
The increased predisposition of HIV/AIDS patients to invasive bacterial isolates has been 
described, but there are no detailed and published data or literatures on the prevalence of 
ESBL-PE in HIV/AIDS infected individuals in Ethiopia. Overuse of antimicrobial agents is 
strongly related to HIV/AIDS infection leading to rapid occurrence of multi-drug resistance 
to the third generation cephalosporins, aminoglycosides and fluoroquinolones that is 
indicative of the emergence of ESBL producing Gram negative bacilli. Therefore, this study 
was designed to look at the existence and magnitude of ESBL-PE among HIV/AIDS patients. 
In line with this study, the findings will provide baseline information for health sector 
administrators and concerned bodies in planning and managing of drug resistance. 
Specifically, to promote specific treatment and preventive measures such as rational 
antibiotic use policy and plan a proper hospital infection control strategy in prevention of the 
dissemination of these strains. It also gives information for physicians for empirical treatment 
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in areas where there is no routine ESBL detection. Furthermore, limiting drugs to those that 
act against the right organisms will help to conserve their efficaciousness which further 
reduces the rate of morbidity, disability and mortality.  
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2. OBJECTIVES 
2.1. General objective 
 To assess the prevalence, antimicrobial susceptibility pattern of ESBL producing 
Enterobacteriaceae  among HIV/AIDS patients  
2.2. Specific objectives 
 To determine the prevalence of ESBL producing Enterobacteriaceae  among 
patients with HIV/AIDS 
 To determine drug susceptibility patterns of ESBL producing Enterobacteriaceae  
isolated from HIV/AIDS patients 
 To determine multidrug resistance patterns of Enterobacteriaceae isolated from 
HIV/AIDS patients  
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3. MATERIALS AND METHODS 
3.1. Study area 
The study was conducted at the University of Gondar Hospital, North Gondar zone of 
Amhara Regional State, North west Ethiopia. University of Gondar Hospital is found in 
Gondar town at a distance of 747 km from the capital city of the country, Addis Ababa and 
182 km from Bahir Dar, the capital city of Amhara regional state. The hospital provides 
services for at least 5 million populations living in and around Gondar including ART 
services for HIV/ AIDS patients. Currently, ART clinic provides services for 5094 ART 
patients and 141 pre-ART patients. 
3.2. Study design and period 
 A Hospital based cross-sectional study was conducted among HIV/AIDS patients from Feb-
May, 2017. 
3.3. Population 
3.3.1. Source population 
The source population was all HIV/AIDS patients seeking health services at the University of 
Gondar Hospital. 
3.3.2. Study population 
The study population was all HIV/AIDS patients seeking ART services during the study 
period at the University of Gondar Hospital ART clinic and willing to give consent. 
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3.4. Inclusion and exclusion criteria 
3.4.1. Inclusion criteria 
Patients who have regular ART follow up were included in the study 
3.4.2. Exclusion criteria 
Patients with a history of antibiotic use for the past seven days, other than ART were 
excluded. 
3.5. Study Variables 
3.5.1. Dependent variable 
 Presence ESBL producing Enterobacteriaceae  
 Drug susceptibility pattern 
3.5.2. Independent variables 
Age, sex, educational status, occupation, residence, previous hospitalization, previous 
surgical procedure, previous exposure to antibiotics, cotrimoxazole prophylaxis therapy and 
adherence, ART status, antibiotic use without physician prescription (self prescription), use 
of oral contraceptives,  level of CD4 count, and AIDS stage.  
3.6. Sample size determination and sampling technique 
3.6.1. Sample size determination 
The sample size was determined using a single population proportion formula as follows:  
N= z2 p (1-p)/ d2; where: N = The number of study subjects from which samples will be 
taken; Z = Standard normal distribution value at 95% CI, which is 1.96; P = the prevalence of 
ESBL-PE infection taken as 50% (0.5) since there is no previous study report in Ethiopia 
exactly on HIV/AIDS patients.  d = the margin of error taken as 5%.   
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Accordingly, the sample size was: 
                                                                     ni= (1.962x0.5x0.5) /0.0025=384 
By considering a 10% non-response rate,       nf= ni+10% of ni =423 
3.6.2. Sampling technique 
On average 40 ART patients/day, 880 patients/month and 2640 individuals were served for 
three months within the study period, which was taken as a sampling frame (N). So, K value 
was N/nf= 6. Then, the study subjects were selected from 1st six subjects randomly and other 
subjects were incorporated in the study for every six of patients by their appearance to the 
ART clinic using a systematic random sampling technique. For study participants who were 
not willing and illegible to participate, the collection procedure was continued with that 
interval for every six cases using the non-response rate till the desired amount of sample was 
collected. Some important data related to patient information like CD4 count of the study 
participants were obtained from the participant chart. 
3.7. Operational definitions  
Previous antibiotic use: Receipt of any systemic antibiotic for >48 hrs for the last 12 
months before 7 days from data collection. 
Level of CD4 count: - CD4 count is the measure of the number of T cells expressing CD4 
which indicate the immune function status in patients who have HIV infection that used for 
deciding when to begin antiretroviral treatment for newly screened patients during HIV 
infection and in this study the cutoff value was considered<500 cells/mm3 based on the 
current national guideline.     
Previous hospitalization: - In this study previous hospitalization of the patient was 
considered if the patient was admitted in the hospital within one year before data collection. 
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Previous surgery history:-In this study previous history of surgery of the patient was 
considered if the patient had a history of any invasive surgery within 6 months before data 
collection. 
Multidrug resistance: - Is resistance to one or more agents in three or more different classes 
of antimicrobials that the isolate is expected to be susceptible (76) 
3.8. Data collection and Laboratory methods 
3.8.1. Questionnaire  
Data on socio-demographic characteristics and ESBL-PE related factors from each study 
participant was collected by a trained data collectors using pretested questionnaire guided 
interview.  
3.8.2. Sample collection and Transport  
Urine sample was collected from a total of 387 HIV patients at the University of Gondar 
Hospital ART clinic. Midstream Clean Catch urine samples were collected from study 
subjects using a sterile wide mouthed container after the participants were given appropriate 
instruction on how to collect urine samples and then  sent to the  laboratory immediately after 
collection using a cold chain.  
3.8.3. Isolation and identification  
The standard microbiological techniques was used for isolation and identification of bacterial 
isolates (61). For isolation and identification, the following media were used: MAC, CLED, 
TSI, LIA, SIM, urea, citrate and lysine decarboxylase. Urine specimen was inoculated on 
CLED agar media using a calibrated wire loop (0.001ml). These inoculated plates were 
incubated in an aerobic atmosphere at 35-37OC for 18-24 hrs. All significantly positive 
cultures were then characterized by a colony characteristic appearance and tested by Gram 
stain. Members of the family Enterobacteriaceae of concern were identified by a series of 
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biochemical tests by testing microorganism’s indole production, lactose fermentation, H2S 
production, citrate utilization, motility test, urease test and lysine decarboxylase test.  
3.8.4. Antimicrobial susceptibility testing  
Antimicrobial susceptibility testing was carried out on each bacterial isolates using Kirby 
Bauer disc diffusion method on Muller Hinton agar (MHA). Briefly, 3–5 pure colonies of 
each bacterium was picked and transferred to a tube containing 5 ml sterile nutrient broth 
(Oxoid) and then mixed thoroughly to make the suspension homogeneous and the suspension 
was adjusted to 0.5 McFarland turbidity standard (Bacterial concentration of 1.5 × 108 colony 
forming unit/ml)  by further addition of colony or incubating suspension at  37°C until the 
turbidity of the suspension adjusted to a 0.5 McFarland turbidity standard for less turbid 
suspensions or by adding a sterile nutrient broth aseptically for over turbid suspensions (85).  
A sterile swab was dipped in the suspension and the entire surface of the Muller Hinton agar 
plate was uniformly flooded with the suspensions and allowed to dry for about 3-15 minutes. 
The antimicrobial impregnated discs were placed in the media using sterile forceps in such a 
way that each disc were placed at least 24 mm away from each other to avoid the overlapping 
of zone of inhibition. After the discs were placed on the inoculated media, the plate was 
allowed to stand for 15 minutes, so that the antibiotic diffused into the media. The plates then 
incubated at 37OC for 18- 24 hrs and observed for the zone of inhibition (86). Grades of the 
susceptibility pattern was recognized as sensitive, intermediate and resistant by comparison 
of zone of inhibition with current standards of clinical laboratory standards institute (CLSI) 
guideline (85). The following antibiotics discs were used in the sensitivity test; cefuroxime 
(30 μg), cefexime (30 μg), cefotaxime (30 μg), cefpodoxime (30 μg), ceftriaxone (30 μg), 
ceftazidime (30 μg), cefepime (30 μg), ciprofloxacin (5 μg), nitrofurantoin (100 μg), 
cotrimoxazole (25 μg), amox-clavulanate (20/10 μg), Amikacin (30 μg) and ampicillin 
(10µg).  
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3.8.5. Testing of the ESBL production 
3.8.5.1. Screening test for ESBL detection 
Screening test for ESBL detection was done according to the CLSI guidelines. Isolates 
showing inhibition zone size below the CLSI stated break points was considered a potential 
ESBL-producer: Cefpodoxime < 22 mm, Ceftazidime < 22 mm, Cefotaxime < 27 mm and 
Ceftriaxone < 25 mm. The sensitivity of screening test for ESBLs in enteric organisms can 
vary depending on which antimicrobial agents are tested. The use of more than one of the 
five antimicrobial agents suggested for screening will improve the sensitivity of detection. 
Cefpodoxime and ceftazidime show the highest sensitivity for ESBL detection as the former 
drug screens for the presence of CTX-M, SHV and TEM derivatives and the later screens for 
SHV and TEM derivatives (87,88). 
3.8.5.2. Phenotypic Confirmatory test 
Extended spectrum beta lactamase detection was carried out by double disc synergy tests 
(DDST) using third generation cephalosporins and modified double disc synergy test 
(MDDST) using cefepime along with the third generation cephalosporins. A negative DDST 
or MDDST was confirmed with combined disc test method.  
A. Double disc synergy test (DDST) 
The double disc synergy test was used as primary isolation method to identify the ESBL 
producing organisms. A 0.5 McFarland’s standard suspension of the test isolates was 
inoculated by using a sterile cotton swab on the surface of a Muller Hinton Agar plates. 
Antibiotic discs of amoxicillin-clavulanic acid (20/10μg) at the center; cefotaxime (30μg) 
and ceftazidime was placed at a distance of 15 mm apart and incubated center to center. After 
incubating overnight at 37˚C that showed a clear extension of cefotaxime and ceftazidime 
inhibition zones towards the disc containing clavulanic acid was considered ESBL producer. 
Isolates which were screened and found positive for ESBL production may be negative for 
confirmatory test using DDST due to the coproduction of other beta lactamases like AMPC 
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lactamase. In such cases, modified double disc synergy test was used using Cefepime 
antibiotics for inhibiting the effect of other beta lactamases (AMPC lactamase). 
B. Modified double disc synergy test (MDDST) 
 Modified double disc synergy test was employed in case the double disc synergy test yields 
a negative result as if the screening test has been positive. The test was performed by using a 
disc of amoxicillin-clavulanate (20/10 μg) along with four cephalosporins (cefotaxime, 
ceftriaxone, ceftazidime and cefepime). A lawn culture of the organisms was made on a 
Mueller-Hinton agar plate. A disc which contained amoxicillin-clavulanate (20/10 μg) placed 
in the center of the plate. The discs of third generation cephalosporin and fourth generation 
cephalosporin was placed 15 mm and 20 mm apart respectively, center to center to that of the 
Amoxicillin clavulanate disc. Any distortion or increase in the zone towards the disc of 
amoxicillin-clavulanate was considered positive for the ESBLs production. For a negative 
MDDST as a result of the effect of coproduction of other enzymes, combined disk test was 
employed. 
C. Combined disc test 
Discs containing 30 μg of cefotaxime, ceftazidime, or cefepime, and discs containing a 
combination of the three drugs plus 10 μg of clavulanic acid were placed independently, 30 
mm apart, on a lawn culture of 0.5 McFarland standard of the test isolate on a Mueller-
Hinton agar plate and incubated for 18-24 hours at 35°C. Depending on the disc type, a 
difference of ≥5 mm between inhibition zone size of the cephalosporin with clavulanate disc 
and cephalosporin alone or a zone expansion of 50%  in cephalosporin with clavulanate disc 
were considered indicating ESBL production (89–91). 
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3.9. Quality control 
The reliability of the study findings was guaranteed by implementing Quality Control (QC) 
measures throughout the whole process of the laboratory work. All materials, equipments and 
procedures were adequately controlled. Pre-analytical, analytical and post-analytical stages 
of quality assurance and standard operating procedures (SOPs) were strictly followed. Pre-
tested questionnaire guided interview was used for data collection on socio-demographic 
characteristics and associated factors. Sterility of culture media was checked by incubating 
5% of the batch at 35-370C overnight and was evaluated for possible contamination. The 
standard reference bacteria strains of K. pneumoniae (ATCC®700603) was used as positive 
control and E. coli (ATCC®-25922 ) was used as negative control of ESBL detection test 
(36,87). Moreover, the whole procedure and result interpretation was cross checked by senior 
laboratory professionals and the potency of antibiotics were monitored using control strains 
based on the following criteria: 
Table 1: Criteria for determining the potency of the test antibiotics 
ESBLs control strain E. coli ATCC 25922 K.pneumoniae ATCC  700603 
Ceftazidime 30 μg 25-32 mm 22-29 mm 
Cefotaxime 30 μg 29-35 mm 18-22 mm 
3.10. Data organization, processing and analysis 
Data was collected, summarized, tabulated and analyzed using SPSS version 20 software. 
The statistical significance association was measured by using the Chi-square test and P 
value < 0.05 was considered statistically significant.  
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3.11. Ethical consideration 
Ethical clearance was obtained from University of Gondar, School of Biomedical and 
Laboratory sciences, ethical review committee and official letter of co-operations was 
provided to the University of Gondar Hospital prior to data collection. Written informed 
consent was obtained from study participants, guardians or caretakers of children after 
explaining the purpose and objective of the study. Any patient, who was unwilling to 
participate in the study, was not forced to participate. They were informed that all data and 
sample obtained from them was kept confidential by using codes instead of any personal 
identifiers and is meant only for the purpose of the study. Laboratory results from the study 
participant were communicated to their physicians for appropriate treatment or management. 
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4. RESULTS 
Socio-demographic characteristics  
A total of 387 HIV/AIDS patients were enrolled in the study. The majority of study 
participants were females 273 (71.1 %) with male to female ratio of 1:2.3. The mean (SD) 
age of the study participants was 37.9 ± 9.7 years. Most of the respondents were in the age 
group of 30-40 years, 159 (41.1%). Besides, 358 (92.5%) of the participants were urban 
residents and 210 (54.3 %) were also participants who had educational level of primary 
school and below (Table 2) 
Table 2: Socio-demographic characteristics of HIV/AIDS patients at the University of 
Gondar Hospital, Feb-May, 2017 
Characteristics Frequency Percent 
Sex 
Male 112 28.9 
Female 275 71.1 
Age 
<30 102 26.4 
30-40 159 41.1 
>40 126 32.6 
Ethnicity 
Amhara 380 98.7 
Tigray 5 1.3 
Religion 
Orthodox 355 91.7 
Muslim 26 6.7 
Protestant 6 1.6 
Residence 
Urban 358 92.5 
Rural 29 7.5 
Occupation 
Unemployed 12 3.1 
Daily laborer 21 5.4 
Housewife 144 37.2 
Merchant 93 24.0 
Farmer 20 5.2 
Employed 97 25.1 
Educational status 
Primary school  and below 210 54.3 
Secondary school 108 27.9 
College/University 69 17.8 
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Distribution of Enterobacteriaceae in patient characteristics  
A total of 387 urine samples were collected from HIV/ADS patients and analyzed 
accordingly. Of these, 42 (10.9%, 95% CI; 7.8-14.3) patients had positive culture for 
Enterobacteriaceae result with a single non-duplicate isolates. In brief, culture positivity rate 
in patients with a history of prior antibiotic use was significantly higher than from those who 
were not (57.1% versus 42.9%, P<0.001). Likewise, a significant high bacterial isolation rate 
was observed in patients with history of antibiotic use without prescription and surgery for 
the past six months (Table 3). As presented in table 4, the most common isolated organisms 
were E.coli 29 (69%), followed by Enterobacter spp six (14.3%) and K.pneumoniae four 
(9.5%). Most importantly, among the isolated Enterobacteriaceae, nine (21.4 %, 95% CI: 
11.9-31) isolates were found to be ESBL producers with highest prevalence of E.coli, four 
(44.4%) followed by K.pneumoniae, two (22.2%), Enterobacter spp. two (22.2%). 
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Table 3: Distribution of Enterobacteriaceae per patient characteristics at the University of 
Gondar Hospital, Feb-May, 2017 
Variables Culture Positivity (Enterobacteriaceae) 
Negative N (%) Positive N (%) P-value 
Sex 
Male 96 (85.7) 16 (14.3) 0.166 
Female 249 (90.5) 26 (9.5)  
Age 
<30 94 (92.2) 8 (7.8) 0.158 
30-40 136 (85.5) 23 (14.5)  
>40 115 (91.3) 11 (8.7)  
Occupation 
 
Unemployed 12 (100) 0 0.805 
Daily laborer 19 (90.5) 2 (9.5)  
Housewife 126 (87.5) 18 (12.5)  
Merchant 82 (88.2) 11 (11.8)  
Farmer 17 (85) 3 (15)  
Employed 89 (91.8) 8 (8.2)  
Educational status 
Primary and below 187 (89) 23 (11) 0.480 
Secondary school 95 (88) 13 (12)  
College/University 63 (91.3) 6 (8.7)  
Previous hospitalization for the past 
12 months 
No 328 (91.9) 29 (8.1)  
Yes 17 (56.7) 13 (43.3) <0.001 
Previous UTI history 
NO 283 (90.4) 30 (9.6) 0.099 
Yes 62 (83.8) 12 (16.2)  
Previous antibiotic history 
No 287 (94.1) 18 (5.9) <0.001 
Yes 58 (70.7) 24 (29.3)  
Antibiotic use without prescription 
No 330 (90.2) 36 (9.8) 0.007 
Yes 15 (71.4) 6 (28.6)  
Surgery history in the last 6 months 
No 329 (90.1) 36 (9.9) 0.011 
Yes 16 (72.7) 6 (27.3)  
Pregnancy 
No 239 (90.9) 24 (9.1) 0.519 
Yes 12 (85.7) 2 (14.3)  
Use of contraceptive 
No 208 (91.6) 19 (8.4)  
Yes 43 (86) 7 (14) 0.217 
Cotrimoxazole prophylaxis 
No 47 (85.5) 8 (14.5) 0.342 
Yes 298 (89.8) 34 (10.2)  
Adherence of cotrimoxazole 
Not completed 68 (93.2) 5 (6.8) 0.279 
Completed 230 (88.8) 29 (11.2)  
ART status 
Pre-ART 16 (80) 4 (20) 0.177 
On ART 329 (89.6) 38 (10.4)  
WHO AIDS staging 
 
Stage I 124 (90.5) 13 (9.5) 0.842 
Stage II 218 (88.3) 29 (11.7) . 
Stage III 2 (100) 0  
Stage IV 1 (100) 0  
CD4 count 
<=499 191 (88.4) 25 (11.6) 0.608 
>=500 154 (90.1) 17 (9.9)  
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Table 4: Percentage of ESBL-PE and non ESBL-PE isolates from HIV/AIDS patients at the 
University of Gondar Hospital, Feb-May, 2017 
ESBL 
enzyme 
production 
                                     Bacterial isolates 
 
E.coli 
N (%) 
K.pneumoniae 
N (%) 
Enterobacter 
Spp. N (%) 
K.ozanae 
N (%) 
K.oxytoca 
N (%) 
Total  
N (%) 
Producer 4 (44.4) 2 (22.2) 2 (22.2) 1 (11.2) 0  9 (100) 
Non 
producer 
25 (75.8) 2 (6.1) 4 (12.1) 1 (3) 1 (3) 33 (100) 
Total  29 (69) 4 (9.5) 6 (14.3) 2 (4.8) 1 (2.4) 42 (100) 
Antimicrobial Resistance pattern of isolated organisms 
The overall antimicrobial resistance pattern of isolates has been presented in Table 5. Of the 
tested antibiotics, all isolates were found to be resistant to Amox-clavulanic acid; nearly 95% 
and 74% of the isolates were also resistant to Ampicillin and Cotrimoxazole, respectively. 
However, the isolates were 100% susceptible to Nitrofurantoin and comparatively, low 
resistance rate was observed to Ceftriaxone (2.4%) and Ciprofloxacillin (2.4%). Besides, 
resistance rate at species level has been also noted in Table 5.  More than 62% E.coli isolates 
were resistant to cefotaxime, cotrimoxazole, ampicillin and amox-clavulanic acid. Relatively, 
low resistance rate was revealed in cefepime (3.4%), ciprofloxacillin (3.4%) and cefuroxime 
(6.9%). All E.coli isolates were sensitive for nitrofurantoin, amikacin, cefpodoxime and 
ceftriaxone. More than 50 % of Enterobacter spps exhibited resistance to cefotaxime, 
ceftazidime, cotrimoxazole, ampicillin and amox-clavulanic acid. Similarly, more than 75% 
of K.pneumoniae isolates posses a resistance character to cefotaxime, ceftazidime, 
cotrimoxazole, ampicillin and amox-clavulanic acid 
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Table 5: Antibiotic resistance pattern of isolated organisms from HIV/AIDS patients at the 
University of Gondar Hospital, Feb-May 2017 
Drugs                                     Bacterial isolates 
E.coli Enterobacter spp K.pneumoniae K.ozanae K.oxytoca Total 
CRX 2 ( 6.9) 0 1 (25) 0 0 3 (7.1) 
CXM 3 (10.3) 1 (16.7) 1 (25) 0 0 4 (9.5) 
CTX 18 (62.1) 3 (50) 3 (75) 2 (100) 0 26 (61.9) 
CAZ 9 (31) 3 (50) 3 (75) 0 0 15 (35.7) 
CTR 0 0 0 1 (50) 0 1 ( 2.4) 
CPD 0 1 (16.7) 1 (25) 0 0 2 (4.8) 
CFP 1 (3.4) 1 ( 16.7) 1 (25) 0 0 3 (7.1) 
CPR 1(3.4) 0 0 0 0 1 (2.4) 
COT 19 (65.5) 5 (83.3) 4 (100) 2 (100) 1 (100) 31 (73.8) 
AMP 27 (93.1) 6 (100) 4 (100) 2 (100) 1 (100) 40 (95.2) 
AMC 29 (100) 6 (100) 4 (100) 2 (100) 1 (100) 42 (100) 
NIT 0 0 0 0 0 0 
AMK 0 0 1(25) 1(50) 1(100) 3(7.1) 
Note: Data are in number (%) unless and otherwise indicated CRX: Cefuroxime, CXM: Cefexime, CTX: 
Cefotaxime, CAZ: Ceftazidime, CTR: Ceftriaxone, CPD: Cefpodoxime, CFP: Cefepime, CPR: Ciprofloxacillin, 
COT: Cotrimoxazole, AMP: Ampicillin, AMC: Amox-clavulanic acid, NIT: Nitrofurantoin, AMK: Amikacin 
Multidrug resistance pattern  
Interestingly, 39 (92.9%; 95% CI: 88.1-97.6%) of isolates showed resistance to three and 
more classes of antibiotics and which were multidrug resistant (MDR) organisms. Only three 
(7.1%) of isolates were found to be non-MDR strains (resistance either for only one or two 
classes of drugs). Briefly, six (100%) of Enterobacter spp., four (100%) of K.pneumoniae, 
two (100%) K.ozanae, one (100%) of K.oxytoca and 26 (89.7%) of E.coli isolates were MDR 
isolates among all isolates (Table 6).  
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Table 6: Multidrug resistance pattern of Enterobacteriaceae among HIV/AIDS patients at the 
University of Gondar Hospital, Feb-May 2017 
Bacterial isolates Degree of antibiotic resistance of isolates 
R2 R3 R4 R5 R6 MDR (≥ R3) 
E.coli (N=29) 3 (10.3) 5 (17.2) 10 (34.5) 8 (27.6) 3 (10.3) 26 (89.7) 
K.pneumoniae (N=4) 0 0 1 (25) 2 (50) 1 (25) 4 (100) 
Enterobacter Spp. (N=6) 0 1 (16.7) 3 (50) 0 2 (33.3) 6 (100) 
K.ozanae (N=2) 0 0 1 (50) 0 1 (50) 2 (100) 
K.oxytoca (N=1) 0 1 (100) 0 0 0 1 (100) 
Total  (N=42) 3 (7.14) 7 (16.67) 15 (35.71) 10 (23.81) 7 (16.67) 39 (92.86) 
Note: MDR: multidrug resistance (R≥ 3 classes); R2: Refers to the resistance of isolates for one and two drugs; 
R3, R4 and R5: Refers to the resistance of isolates for 3, 4 and five drugs; R6: Refers to the resistance of 
isolates for 6 and above drugs 
 
Moreover, the total resistance pattern of ESBL-PE isolates are presented in the fig.3. All 
ESBL producing isolates were 100 % resistant to ampicillin and amox-clavulanic acid and 
88.9 % resistance to cefotaxime and ceftazidime, but least resistance was observed for both 
ceftriaxone and cefpodoxime. All ESBL-PE isolates were MDR for tested antimicrobials and 
30 (90.9%) of non ESBL-PE isolates were MDR.  Antibiotic resistance rate of ESBL-PE 
isolates was significantly higher than non-ESBL-PE strains for some of tested antimicrobials 
like cefuroxime (22.2% versus 3%; p=0.048), ceftazidime (88.9% versus 21.2%; p<0.001), 
cefepime (22.2% versus 3%; p=0.048) and Amikacin (22.2% versus 0%; p=0.006). But, 
significant variation was not observed for the following antibiotics; cefexime, cefotaxime, 
ceftriaxone, cefpodoxime, ciprofloxacillin, cotrimoxazole, ampicillin, amox-clavulanic acid 
and nitrofurantoin  
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Figure 1: Antibiotic resistance rate of ESBL-PE isolates in comparison with non ESBL-PE 
isolates among study participants at the University of Gondar Hospital, Feb-May, 2017 
 
 
 
                                                                                                                                                                                                                                                                            
Antibiotics 
CRX CXM CTX CAZ CTR CPD CFP CPR COT AMP AMC NIT AMK 
p value a 0.048 0.281 0.060 <0.001 0.053 0.313 0.048 0.453 0.760 0.449 - - 0.006 
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5. DISCUSSION 
It is a known that HIV/AIDS infection complicates the treatment of infection by increasing 
morbidity, mortality and increasing the risk of recurrent infections after treatment has been 
successfully completed. It is largely understood that HIV infection down regulates for cell 
mediated immune response during bacterial infection. The viral infection also predisposes 
loss of integrity of natural mucosal barriers and subsequently leads to high rate of bacterial 
infection. Therefore, the HIV/AIDS patients are highly vulnerable for repeated opportunistic 
infection which intern exposes for repetitive antimicrobial treatments as well as increased 
rate of hospitalization. As a result, these patients stand to the front line to be exposed for 
multidrug resistant organisms or to develop these organisms through selective pressure due to 
repeated exposure for antibiotics (62).  
The upward trend in the prevalence of pathogens producing ESBLs is of increasing clinical 
concern related with the increased prescription of beta lactam drugs. Infections with these 
drug resistant strains continue to be associated with higher rates of mortality, morbidity and 
health care costs (55). Global reports have shown that considerable differences exist in the 
occurrence and proportion of ESBL-producing isolates in different countries. Besides, the 
overall epidemiology of drug resistant strains namely ESBL-PE doesn’t well appreciated in 
resource limited countries (31,56). 
Among the study participants, the overall prevalence of ESBL-PE infection was found to be 
21.4% which is comparable with reports indicated in  Jordan (22.9%) (61) Saudi Arabia 
(22%) (83) and Nigeria (17.3) (62). However, the prevalence noted in the present study was 
significantly higher compared with that documented in studies from USA (8.6%) (57), UK 
(1%) (58). On the other hand, it was lower than reports from different Asian countries like 
United Arab Emirates (41%) (55), India (38.83%) (60) and African countries like Ghana 
(49.3%) (63), Uganda (62 %) (64), Burkinafaso (58%) (65). The variation might be due to 
the fact that difference in sampling population, policy of antibiotics prescription, socio-
cultural and economic factors. 
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In Ethiopia, there are still limited evidences regarding with the prevalence ESBL-PE. A 
report claims that on the  prevalence of ESBL-PE in Adama, Ethiopia was 25% (31), which 
is comparable with the finding of the current study. However, in studies from other part of 
Ethiopia like, Jimma (38.4) (9), Addis Ababa (52%) (47) and Harar (33.3%) (54) had 
reported a higher prevalence of ESBL-PE than the current study. Lower prevalence of ESBL-
PE of the current study compared with aforementioned reports might be related with 
variability of sampling population and methodological difference. Additionally, the present 
study reports the prevalence among HIV patients with both symptomatic and asymptomatic 
UTI cases that could underestimate the result.  
Although there are differences in proportion, several studies had reported that E. coli and K. 
pneumoniae (9,47,55,58,62,64,83) were the most prevalent pathogens among the ESBL 
producing isolates in different geographical regions in agreement with our study where E.coli 
(44.4%) followed by  K.pneumoniae (22.2%) and Enterobacter spp (22.2%) were 
predominantly isolated pathogens. The varying proportion of isolates with regarding to 
production of ESBL in different studies in different areas might be attributed with variation 
in geographical distribution of isolates, sample size, detection methodology used in each 
investigation and target population. The highest prevalence of E.coli isolation among total 
isolates in HIV/AIDS in UTI cases might be related with its virulence factor that E.coli has a 
virulence factor that will enable to attach to the walls of the renal tubules through Pilli so that 
will not be removed with renal flow rather moves to the opposite direction of the flow of 
urine. As a result, E.coli will have a high proportion of isolation in UTI cases. 
In the current study, very high resistance of microorganisms was reported to Amox-
clavulanic acid (100%), followed by Ampicillin (95.2%), Cotrimoxazole (73.8%), 
Cefotaxime (61.9%) and Ceftazidime (35.7%) among all isolates in agreement with other 
report (9). This high resistance rate to these drugs might be related with a high rate of 
prescription of these drugs as a routine therapy and as a prophylaxis therapy in case of 
cotrimoxazole in HIV/AIDS patients in clinical setups. Additionally, the frequent exposure 
of HIV/AIDS patients to these antibiotics as a result of frequent infection related with 
reduced immunity as well as increased rate of hospitalization. On the other hand, all isolates 
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were susceptible for Nitrofurantoin. This is presumably due to Nitrofurantoin is not a 
commonly used antibiotics for empirical treatment of bacterial infection that preserves the 
potency of the drug. Hence, it is good if nitrofurantoin is used as an alternative treatment 
choice in treating resistant isolates. 
 Regarding to multidrug resistance, the overall MDR rate of all isolated Enterobacteriaceae 
in the current study was 92.9%. The highest prevalence of MDR might be related to different 
factors. Primarily, due to poor sanitation, inadequate health care services and poor access to 
drugs; the other factor is related with health care provider related factors in that the health 
care professionals sell the antimicrobials to patients or receive a kick back fee or other 
incentives by referring the patients to a particular pharmacy and even prescribe 
presumptively when there are no clinical indications. Additionally, patient related factors in 
that the patients believe and perceive that most infections respond to antibiotics and expect to 
be antibiotics by health care providers for those of non specific symptoms that may might not 
be even any particular infection. As these factors are highly pronounced in HIV/AIDS 
patients, the rate of MDR might be more pronounced in HIV /AIDS patients (10). 
The prevalence of MDR (92.9%) among Enterobacteriaceae uropathogens was also assessed 
in this study. The finding of this study is comparable with reports in Gondar (93.5%) (74), 
Bahirdar (92.2%) (72) and  Hawasa (90.8%) (69). But, it is higher than figures reported in 
Gondar (87.4%) (73), Dessie (74.9%) (71).  However, it was lower than reports from Jimma 
(100%) (70). It is also indicated that the prevalence of MDR in the current study is higher 
than other reports like Mozambique (88.2%) in Africa (68) and other countries, such as USA 
(19.1%) (66), Nepal (41.1%) (67). The variation in prevalence of MDR Enterobacteriaceae 
isolates could be due to increase trend of MDR strains with time, difference in study period 
and study population. Moreover, high prevalence of MDR was observed among ESBL-PE 
(100%) than non producing isolates (90.9%) as demonstrated in various reports (9,62) which 
might be associated with unique property of the large ESBL plasmid, which is capable of 
incorporating and subsequently coding for resistant determinants to non beta-lactam 
antimicrobial agents in addition to beta lactam drugs. 
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6. LIMITATIONS OF THE STUDY 
The current study has not sought molecular patterns of ESBL-PE isolates to demonstrate 
which molecular type was prevalent.  
7. CONCLUSION  
An alarming prevalence of ESBL-PE isolates were observed among HIV/AIDS patients and 
the E. coli and K. pneumonia were the most common ESBL-PE isolates. All ESBL producing 
isolates were MDR for all tested antimicrobial agents. Antibiotic resistance rates in ESBL 
producing isolates were comparatively higher than other ESBL non producing isolates.  
8. RECOMMENDATION  
Therefore, the current study indicates that the prevalence of ESBL producing isolates are 
alarmingly increasing that demands for the  efforts should be made to reduce patient hospital 
stay and maximize rational use of drugs. Additional and vigorous investigation especially on 
ESBL producing isolates should be encouraged. There should also be a trend of routine 
screening of clinical isolates for ESBL production in clinical settings. It is also recommended 
that infection control practices should be strictly implemented to avoid the spread of resistant 
strain especially ESBL-PE. Most importantly, local antimicrobial susceptibility testing has to 
be promoted for the best management of HIV/AIDS patients.  
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ANNEXES 
Annex I: Information sheet and consent form 
Study Title: Extended spectrum beta lactamases producing Enterobacteriaceae among HIV 
patients: Prevalence, antimicrobial susceptibility pattern and associated risk factors in 
University of Gondar Hospital, North west Ethiopia    
Name of the Sponsor:  Amhara Regional Health Bureau 
Name of the Organization:   School of Biomedical and Laboratory Sciences, Gondar 
College of Medicine and Health Sciences, University of Gondar. 
1. Purpose of the Research Project: The aim of this study is to assess the prevalence of 
extended spectrum beta lactamase producing Enterobacteriaceae isolated from clinical 
samples among HIV patients attending at University of Gondar hospital, Gondar, North West 
Ethiopia. In line with the findings, it will provide a baseline information for health sector 
administrators and concerned bodies in planning and managing of drug resistance that allow 
to devise treatment and preventive measures such as a rational antibiotic use policy and plan 
a proper hospital infection control strategy to prevent the dissemination of these strains.  
2. Procedure: In order to perform the indicated study at University of Gondar hospital you 
are invited to take part in this project. If you are willing to participate, you need to 
understand the purpose of the study and give your consent. The required clinical sample will 
be collected by trained Laboratory technologists who are currently working in ART 
laboratory of the hospital. Then, you will be requested to give your consent to the sample 
collector. Socio-demographic, associated factors and clinical information will be collected 
from the study participants using structured questionnaires via interview technique; since you 
fulfill the criteria you are kindly requested to give the  required sample and genuine answers 
to the prepared questionnaire. 
3. Risk associated with the study: You will not be at any physical or psychological risk and 
no damage resulting from the research procedures but during collection of the blood you may 
feel some discomfort, this will not produce serious pain. 
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4. Benefits of the study:  Based on the diagnosis result you will be treated accordingly. 
Moreover, this study will have a great value on preventive measures in hospitals and in the 
community. The results of this study have importance to treat the patients and to use as a 
baseline for effective treatment in the absences of laboratory investigation for empirical 
treatment of infections. 
5. Compensation for participation:  You will not receive any payment for your 
participation in this research study. 
6. Confidentiality of your information- All information gathered from the study participant 
will remain confidential. Your participation in this study is strictly anonymous. Personal 
information will be treated confidentially and under no circumstances will it be transmitted to 
any person or organization. The results of this study will be evaluated and summarized, and a 
feedback of the results to the study participants will be given by principal investigator. 
7.  Right to Refusal or Withdraw:  Your participation in the study is absolutely voluntary; 
you have full right to refuse from participating in this research. You can refuse to give   
sample and not to respond any or all the questionnaires and this will not affect you on using 
any kind of services from the hospital. 
8. Person to Contacts:  This research project will be reviewed and approved by Ethical 
review committee of School of Biomedical and laboratory Sciences, College of Medicine and 
Health Sciences, university of Gondar. If you want to know more information, you can 
contact the following individuals and you may ask at any time.  
1. School of Biomedical and Laboratory Sciences, UGO 
 P.Box-196, Gondar, Ethiopia 
2. Mr. Demeke Endalamaw, principal investigator 
Mobile: +25193404064/ e-mail: demekeendalamaw@gmail.com 
3. Mr Setegn Eshetie,(advisor), University of Gondar  
 Mobile:  0947050546/e-mail: wolet03.2004@gmail.com 
4. Mr Anteneh Amsalu,(advisor), University of Gondar 
Mobile: +251910047320 e-mail: ant.amsalu@gmail.com 
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Consent form 
Serial No------------------Name of health institution----------------------Card No---------------         
Date-------------- 
I, the undersigned study participant have been well-informed about the objective of the study 
entitled "Extended spectrum beta lactamases producing Enterobacteriaceae among HIV 
patients: Prevalence, antimicrobial susceptibility pattern and associated risk factors in 
University of Gondar Hospital, North west Ethiopia"    
Name of the Sponsor:  Amhara Regional Health Bureau 
I am also told that all the information obtained at any course of the study is to be kept 
confidential. Moreover, I have also been well-informed of my right to keep hold of, decline 
to cooperate and drop out of the study if I want and none of my actions will have any bearing 
at all on my overall health care and hospital access. 
I agreed voluntarily to provide the requested samples from me as well as my child. 
Name and signature of study participant _________________ Date_____________  
Name and signature of investigator   ________________   Date_____________ 
Assent form for child 
I have read and/or listened to the description of the study and I understand what the 
procedures are and what will happen to me in the study. I have received permission from my 
parents/guardian(s) to participate in the study and I have agreed to participate in the study. I 
know that as I can stop the study at any time. 
 ________________________________     _____________________ 
   Signature of Child                                                    Date 
 ________________________________     _____________________ 
  Signature Investigator                                                 Date 
Annex II: Amharic Version Study Participant Information and Consent Form 
የመረጃና የስምምነት ዉል ቅጽ  
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 የጥናቱ ርእስ - እስከ 3ኛ ደረጃ ያሉትን የሴፋሎሰስፖሪን ዝርያ ፀረ-ባክቴሪያን የተቋቋሙ 
የባክቴሪያ ዝርያዎችን በጎንደር ዩኒቨርሲቲ ሆስፒታል በሚታከሙ የ ኤች ኤይ ቪ ሕመምተኞች 
በማንኛውም ናሙና ውስጥ መኖራቸውን መለየት፤ በምን ያህል መጠን እንዳሉ ማወቅ፤ በምን 
መድሃኒት ሊድኑ እንደሚችሉ እና ለበሽታው አጋላጭ የሆኑ ሁኔታዎችን ማወቅ፡፡ 
የጥናቱ ደጋፊ - የአማራ ብሔራዊ ክልላዊ መንግስት ጤና ቢሮ፡፡ 
የድርጅቱ    ስም-ጎንደር  ዩኒቨርሲቲ ህክምና ና ጤና ሳይንስ ኮሌጅ የላቦራቶሪ እና ባዮሜዲካል 
ትምህርት ቤት  
1. የጥናቱ ዓላማ- እስከ 3ኛ ደረጃ ያሉትን የሴፋሎሰስፖሪን ዝርያ ፀረ-ባክቴሪያ የተቋቋሙ 
የባክቴሪያ ዝርያዎችን በጎንደር ዩኒቨርሲቲ ሆስፒታል በሚታከሙ ህመምተኞች በማንኛውም 
ናሙና ውስጥ መኖራቸውን መለየትና፤በምን ያህል መጠን እንደሚገኙ ማወቅ እና በምን 
መድሃኒት ሊድኑ እንደሚችሉ ማወቅ ነው፡፡አያይዞም ከጥናቱ የሚገኘው ውጤት ለጤና 
ተቋም አስተዳዳሪዎች ለሚመለከታቸው አካላት እና ለሕሙማን ለራሳቸው በዚህ ጀርም 
የሚከሰተውን ሕመምና ሞት ለመከላከል መሠረታዊ መረጃዎችን ይሰጣል፡፡ 
2.  የአሰራር ሂድት- ይህን ጥናት በጎንደር ዩኒቨርሲቲ ሆስፒታል ለመስራት የጥናቱ  ተሳታፊ 
እንዲሆኑ ተጋበዘዋል፡፡ ለመሳተፍ  ፍቃደኛ  ከሆኑ  የጥናቱን ዓላማ መረዳትና 
ፍቃደኝነትዎን መግለፅ ይጠበቃል፡፡ለዚህ ጥናት የሚያስፈልገው ናሙና  የሚሰበሰበው 
በናሙና አሰባሰብ ዙሪያ በቂ ስልጠና በወሰዱ ባለሙያወች ይሆናል፡፡እንዲሁም በተጨማሪ 
ማህበራዊ ነክ  አጋላጭ ሁኔታዎች እና የጤንነት  ሁኔታን የሚያሳዩ ጥያቀዎች  
ከያንዳንዱ የጥናቱ ተሳታፊዎች  በመጠይቁ መሰረት ይሰበሰባል፡፡እርስዎም  መስፈርቱን  
እስካሟሉ ድረስ  የሚያስፈልገዉን ናሙና ለመስጠት  እና ለተዘጋጀው ጥያቄ ትክክለኛ 
ምላሽ እንዲሰጡ በትህትና  ይጠየቃሉ፡፡ 
3. ከጥናቱ ጋር ተያይዞ የሚመጣ ጉዳት - በዚህ ጥናት ዝርዝር አሰራር ሂደት ውስጥ አካላዊ 
ወይም አእምሮአዊ ጉዳት አይኖርም፡፡ ነገር ግን ናሙናዉ በሚወሰድበት ጊዜ መጠነኛ የሆነ 
የህመም ስሜት ሊሰማዎት ይችላል፡፡ ቢሆንም ይሀ የህመም ስሜት ምንም አይነት ችግር 
አያመጣብዎትም፡፡ 
4. ጥቅሞች - በምርመራ ውጤትዎ መሠረት ሕክምና ያገኛሉ በተጨማሪም ይህ ጥናት 
የመከላለል ስራ በሆሰፒታል እና በህብረተሰቡ ዘንድ እንዲኖር ያግዛል፡፡ እንደዚሁም ደግሞ 
የላቦራቶሪ አገልግሎት በሌለበት ጤና ተቋም ትክክለኛ መድሃኒት ለመስጠት እንደ አመላካች 
ሆኖ ያገለግላል፡፡ 
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5. ለተሳትፎ የሚሰጥ ማካካሻ- ምንም አይነት የካሳ ክፍያ የለዉም 
6. የጥናቱ መረጃ ሚስጥራዊነት- ሁሉም ከተሳታፊዎች የሚሰበሰቡ መረጃዎች በሚስጢር 
የሚያዙ እና የሚጠበቁ ይሆናሉ፡፡ በማንኛውም ምክንያት ተሳታፊዎች እነማን መሆናቸውን 
የሚያሳይ በመጠይቁ ይሁን በሌላ ነገር አይኖርም፡፡ የተሰበሰቡ መረጃዎች ለሶስተኛ ወገን 
ተላልፎ አይሰጥም፡፡ በተጨማሪም ውጤቱ የሚለካዉ ይሁን ተሰብስቦ የሚያዘው በዋና 
አጥኚ ነው፡፡ 
7. የመዉጣት (የማቋረጥ) መብት -  በዚሀ ጥናት ላይ መሳተፍዎ በሙሉ ፍቃደኝነት ላይ 
የተመሰረተ ነው ::ጥናቱን የማቋረጥ ሙሉ መብት አለዎት ፡፡ ናሙናም ሆነ ለመጠይቁ 
መልስ ያለመስጠት ከሆስፒታሉ የሚያገኙትን ማንኛውንም አገልግሎት አይገድብም ፡፡ 
8. የሚያገኙዋቸው ሰዎች- ይህ ጥናት በጎንደር ዪኒቨርሲቲ የስነምግባር ምርምር ኮሚቴና 
ሕክምናና ጤናሳይነንስ ኮሌጅ የላቦራቶሪ ባዮሜዲካል ትምህርት ክፍል ተዕልኮ የሚጸድቅ 
ይሆናል፡፡ጥያቄ ካለዎት ተጨማሪ መረጃ ከፈለጉ በማንኛዉም ጊዜ ከዚህ በታች 
የተጠቀሰዉን አድራሻ መጠቀም ይችላሉ፡፡  
1.  ባዮ ሜዲካል እና ላቦራቶሪ ሳይንስ፡፡ 
                       ፐ.ሳ ቁ-196, ጎንደር ኢትዮጵያ 
2. ደመቀ እንዳላማው   ዋና ተመራማሪ:   
    ስ.ቁ:+251913404064፣ ኢ.ሜል demekeendalamaw@gmail.com 
3. አቶ ሰጠኝ እሸቴ፤ አማካሪ    ጎንደር  ዩንቨርሲቲ 
    ስ.ቁ:+251947050546፣ ኢ.ሜል: wolet03.2004@gmail.com 
4. አቶ አንተነህ አምሳሉ፤ አማካሪ    ጎንደር  ዩንቨርሲቲ 
    ስ.ቁ:+251910047320፣ ኢ.ሜል: ant.amsalu@gmail.com 
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የስምምነት ዉል 
የአዋቂዎች የስምምነት ማረጋገጫ ፊርማ                                                                                   
ተራ ቁጥር---------------የሚታከምበት ጤና ተቋም---------------------የካርድ ቁጥር------------- 
ቀን-------------------------  
እኔ ከዚህ በታች ስሜ የተጠቀሰዉና የፈረምኩት የጥናቱ ተሳታፊ እስከ 3ኛ ደረጃ ያሉትን 
የሴፋሎሰስፖሪን ዝርያ ፀረ-ባክቴሪያን የተቋቋሙ የባክቴሪያ ዝርያዎችን በጎንደር ዩኒቨርሲቲ 
ሆስፒታል በሚታከሙ የ ኤች ኤይ ቪ ሕመምተኞች በማንኛውም ናሙና ውስጥ መኖራቸውን 
መለየት፤ በምን ያህል መጠን እንዳሉ ማወቅ፤ በምን መድሃኒት ሊድኑ እንደሚችሉ እና ለበሽታው 
አጋላጭ የሆኑ ሁኔታዎችን ለማሳወቅ የሚደረገውን ጥናት አላማና ጥቅም በሚገባ ተረድቻለሁ፡፡ 
ጥናቱ ላይ መሳተፍም ሆነ አለመሳተፍ በራሴ ፍቃድ የሚወሰን መሆኑም ተገልጾልኛል፡፡ 
በተጨማሪም ከጥናቱ ባልሳተፍም ሆነ አቋርጨ ብወጣ ከሆስፒታሉ በማገኘዉ የህክምና አገልግሎት 
ምንም አይነት ችግር እንደማይደርስብኝ ተነግሮኛል፡፡በመሆኑም ከእኔም ሆነ ከልጄ ናሙና መዉሰድ 
አስፈላጊ መሆኑን ስለተስማማሁበት ለመስጠት ሙሉ ፈቃደኛ መሆኔን በፊርማዬ እገልጻለሁ፡፡ 
የተሳታፊ ስምና ፊርማ ________________ ቀን _____________________ 
የተመራማሪ ስምና ፊርማ _____________ቀን ____________________ 
የልጆች የስምምነት ማረጋገጫ ፊርማ 
እኔ የጥናቱ ተሳታፊ የጥናቱን ሂደት እና በጥናቱ ጊዜ ስለሚያጋጥሙኝ ነገሮች በሚገባ የተረዳሁና 
በጥናቱ ለመሳተፍ ከአሳዳጊዎቼ/ ከቤተሰቦቸ ፍቃድ አግንቻለሁ፡፡ ከጥናቱ በማንኛዉም ደረጃ እራሴን 
ማግለል እንደምችል ተረድቻለሁ እናም በጥናቱ ለመሳተፍ ተስማምቻለሁ፡፡  
 
የተሳታፊዉ ልጅ ፊርማ-------------------------------ቀን--------------------- 
የዋና ተመራማሪ ፊርማ-------------------------------ቀን--------------------- 
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Annex III: Questionnaire & Laboratory data collection form 
Investigation of Extended spectrum beta lactamases producing Enterobacteriaceae among 
HIV patients: Prevalence, antimicrobial susceptibility pattern and associated risk factors in 
the University of Gondar Hospital, Gondar, North west Ethiopia from Jan 1-March 31, 2017 
Annex III a: Questionnaire: 
Code No  
Hospital Card No  
Date of sample collection  
Health Organization  
Section 1: Demographic information: 
S. No   Question  Code  Response  
Q101 Sex 0 = Male, 1 = Female  
Q102 Age    ---------- Years  
Q103 Ethnicity  ----------------------------- 
Q104 Religion  __________ 
Q105 Residence  0 = Urban, 1 = Rural   
Q106 Occupation    
Q107 Education status  1 = No education,     2 = Primary schools,             
3 = Secondary schools   4 = College/University  
 
Section 2: clinical information  
S. No  Questions  Code  Response  
Q201 Patient Type 0= outpatient,   1 = inpatients   
Q202 If admitted patient, admission ward: __________Date of admission: ___________ 
Q203 Admitted to this health care 
facility from 
0 = home 1=other health facility   
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Section 3: Risk factor for ESBL-PE: please tick box (es) that apply to this patient  
S. No  Questions  Code Response  
Q301 Previous hospitalization for the past 12 
months, If yes, for how long days/weeks? 
0= No 1= Yes  
----------------- 
 
Q302 ICU admission  for the past 12 months  0 = No  1= Yes  
Q303 Previous UTI infection  for the past 12 
months 
0 = No  1= Yes  
Q304 Previous antibiotic therapy?  If yes, what type 
of drug have you been taking? 
0 = No  1= Yes 
------------- 
 
Q305 Antibiotic use without prescription  0 = No  1= Yes  
Q306 Presence of urinary catheter  0 = No      1= Yes  
Q307 Mechanical ventilation  0 = No      1= Yes  
Q308 Surgery in the last 6 months  0 = N        1= Yes  
Q309 Chronic diseases (Diabetes, malignancy….) 0 = No      1= Yes  
Q310 Pregnancy  0 = No       1= Yes  
Q311 Use of contraceptive  0 = No       1= Yes  
Q312 History of  haemodialysis   0 = No        1= Yes  
Q313 Use of Cotrimoxazole prophylaxis therapy 0 = No      1= Yes  
Q314 If yes, for Q 14, was completed? 0 = No      1= Yes  
Q315 ART status 0 = Not on ART    
 1= on ART 
 
Q316 WHO AIDS staging 1=Stage 1,  2=stage 2 
3=Stage 3,  4=Stage 4 
 
Q317 CD4 count? (Observe the patient chart)  -------------  
Q318 None of the risk factors apply to this patient 0 = No      1= Yes  
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Annex III b: Laboratory data collection form:  
Code No  
Hospital Card No  
Date of sample collection  
Health Organization  
 
S. No Question  Code  Response  
1.  
 
 
Enterobacteriaceae  
 
1 =E.  coli,                     2 = k. pneumonia 
3 = Proteus spp.          4 = Enterobacter spp. 
5 = Citrobacter spp.    6 = other  
 
 
2.  ESBL-PE  0 = No   1 = Yes  
3. Antibiotic susceptibility pattern: 
Antibiotic Sensitivity Results (CLSI, 2017): Zone diameter breakpoints nearest to 
whole mm 
Content S I R Reading (mm)  Interpretation 
Cefuroxime 30µg      
Cefexime 30µg      
Cefotaxime 30µg      
Ceftazidime 30µg      
Ceftriaxone 30µg      
Cefpodoxime 30µg      
Cefepime 30µg      
Ciprofloxacin  5µg      
Cotrimoxazole 25µg      
Ampicillin 10µg      
Amikacin 10µg      
Amox-clav 30µg      
Nitrofurantoin 30 µg      
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Annex IV: Amharic Version of Questionnaire  
    የአማርኛ መጠይቅ  
እስከ 3ኛ ደረጃ ያሉትን የሴፋሎሰስፖሪን ዝርያ ፀረ-ባክቴሪያን የተቋቋሙ የባክቴሪያ ዝርያዎችን 
በጎንደር ዩኒቨርሲቲ ሆስፒታል በሚታከሙ የ ኤች ኤ ቪ ሕመምተኞች በማንኛውም ናሙና ውስጥ 
መኖራቸውን መለየት፤ በምን ያህል መጠን እንዳሉ ማወቅ፤ በምን መድሃኒት ሊድኑ እንደሚችሉ 
እና ለበሽታው አጋላጭ የሆኑ ሁኔታዎችን ለማወቅ የተዘጋጀ መጠይቅ፡፡ 
የኮድ ቁጥር  
የመታከሚያ ካርድ ቁጥር  
ናሙናዉ የተወሰደበተ ቀን  
የጤና ተቋሙ ስም  
ሀ. ማህበራዊ ና ኢኮኖማዊ መረጃ፤ 
ተ.ቁ ጥያቄ መለያ ምልክት ምላሽ 
1.  ፆታ   0 = ወንድ, 1 =ሴት  
2.  እድሜ   ---------- አመታት  
3.  ብሄር   ----------------------------- 
4.  ሐይማኖት       __________ 
5.  መኖሪያ ቦታ 0 = ከተማ, 1 = ገጠር  
6.  ሥራ   
7.  የትምህርት ደረጃ 1= ያልተማረ         2= የመጀመሪያ ደረጃ  
3= የሁለተኛ ደረጃ     4= የከፍተኛትምህርት 
 
ለ. ክሊኒካል መረጃዎች 
ተ.ቁ  ጥያቄ  መለያ ምልክት ምላሽ 
1.  የታካሚዉ   አይነት 0= ተመላላሽታካሚ,1= ተኝቶታካሚ  
2.  ተኝቶታካሚ ከሆነ የተኛበት ክፍል__________የተኛበት ቀን___________ 
3.  ታካሚው ወደ ጤና ተቋሙ የመጣው  0=  ከቤቱ 1= ከሌላ ጤና ተቋም  
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ሐ. ለበሽታው መባባስ አጋላጭ ሁኔታዎች 
ተ.ቁ  ጥያቄ  መለያ ምልክት ምላሽ 
1.  ላላፉት12 ወራት ሆስፒታል ተኝተው ያውቃሉ? 0= አይደለም 1= አዎ  
2.  ላላፉት12 ወራት በፅኑ ታመው ሆስፒታል ተኝተው 
ያውቃሉ? 
0= አይደለም 1= አዎ  
3.  ላላፉት12 ወራት የ ሽንት ቱቦ ታመው ነበር?  0= አይደለም 1= አዎ  
4.  ፀረ-ባክቴሪያ መደሃኒት ወስደው ያውቃሉ? ስሙን 
ይጥቀሡ? ለምንያህልጊዜ? 
0= አይደለም 1= አዎ  
5.  ከሃኪም  ትዕዛዝ ዉጪ መድሃኒት የመግዛት ልምድ 
አለዎት? 
0= አይደለም 1= አዎ  
6.  የሽንት ማሸኛ ቱቦ ተገጠሞለዎት ያውቃል? 0= አይደለም 1= አዎ  
7.  አየር መቅዘፊያ መሳሪያ ይጠቀማሉ? 0= አይደለም 1= አዎ  
8.  ላለፉት 6 ወራት ቀዶ ጥገና አድርገው ያውቃሉ? 0= አይደለም 1= አዎ  
9.  ስር የሠደደ  ወይም ለረጅም ጊዜ የቆየ እንደ ስኳር 
ዓይነት   ህመም አለብዎት? 
0= አይደለም 1= አዎ  
10.  የእርግዝና ሁኔታ 0= የለም  1= አለ  
11.  የእርግዛና መከላከያ መድሃኒት ይጠቀማሉ? 0= አይደለም 1= አዎ  
12.  የኩላሊት እጥበት ዐካሂደው ያውቃሉ? 0= አይደለም 1= አዎ  
13.  ኮትሪሞክሳዞል የተባለውን መድሃኒት ለቅድመ 
መከላከያ ተጠቅመው ያውቃሉ? 
0= አይደለም 1= አዎ  
14.  መልሥዎ አዎ ከሆነ የታዘዘልዎትን በሙሉ 
ጨረሰዋል? 
0= አይደለም 1= አዎ  
15.  የ ኤ አር ቲ መድሃኒት ጀምረዋል? 0= አይደለም 1= አዎ  
16.  በአለም ጤና ድርጅት የበሽታው ደረጃ 1= ደረጃ 1, 2= ደረጃ 2 
3= ደረጃ 3,  4= ደረጃ 4 
 
17.  ማንኛውንም አጋላጭ መንስኤዎች እርስዎ ላይ 
ተግባራዊ አይሆንም? 
0= አይደለም 1= አዎ  
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Annex V: Procedures 
A. Urine Specimen collection 
 
1. Instruct the patient to clean the urethral area thoroughly to prevent external bacteria from 
entering the specimen. 
Important: Explain to the patient the need to collect the urine with as little contamination as 
possible, i.e. a clean-catch’ specimen.  
A. Female patients: Wash the hands. Cleanse the area around the urethral opening with clean 
water, dry the area with a sterile gauze pad, and collect the urine with the labia held apart.  
B. Male patients: Wash the hands before collecting a specimen (middle of the urine flow). 
Note: When a patient is in renal failure or a young child, it may not be possible to obtain 
more than a few milliliters of urine  
2. Give the patient a sterile, dry, wide-necked, leak proof container and request to bring 10–
20 ml urine specimen.  
3. Let the patient void into the container. 
4. Label the specimen container with patient identifying information, and send to the lab 
immediately. A delay in examining the specimen may cause a false result. 
5. Wash your hands and instruct the patient to wash his hand as well 
B.  Culture media preparation 
1. Read the manufacturer’s instructions on the bottle of dehydrated agar media of interest. 
2. Measure the appropriate amount of dehydrated powder media and distilled water using an 
electronic balance on clean dry paper and measuring cylinder respectively.    
3. Drop a measured amount of distilled water in an Erlymeyer flask and add the measured 
amount of powder. 
4. Close  the flask with cotton foiled with aluminum foil 
5. Heat  the flask on a hot plate  to dissolve the mixture until it vapors 
6. When the agar mixture is completely dissolved, remove the flask from the hot plate 
7.  Autoclave the agar mixture for 15 min at 120oc. Do not autoclave the preparation if 
indicated in the manufacturer’s instruction. 
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8. Remove the flask of sterilized agar from autoclave and allow it to cool to about 50°C. 
9. Quickly pour the melted, sterile agar into a series of petri dishes until about one-third of 
the dish is filled and wait until it solidifies by partially covering the dishes. 
10. Invert the petri dishes if the agar is solidified to avoid the moisture from accumulating on 
the agar surfaces that has been condensed from the vapor. 
11. Incubate one petridish from each batch of preparation in the incubator from for at least 24 
hours to check sterility of preparation before use. 
C. Gram stain procedures 
1 Fix the dried smear as explained in subunit 7.3.2. Note: When the smear is for the 
detection of gonococci or meningococci, it should be fixed with methanol for 2 
minutes (avoids damaging pus cells). 
2  Cover the fixed smear with crystal violet stain for 30–60 seconds. 
3 Rapidly wash off the stain with clean water. Note: When the tap water is not clean, 
use filtered water or clean boiled rainwater. 
4  Tip off all the water, and cover the smear with Lugol’s iodine for 30–60 seconds. 
5 Wash off the iodine with clean water. 
6 Decolorize rapidly (few seconds) with acetone–alcohol. Wash immediately with clean 
water. Caution: Acetone–alcohol is highly flammable; therefore use it well away 
from an open flame. 
7 Cover the smear with neutral red stain for 2 minutes. 
8 Wash off the stain with clean water. 
9 Wipe the back of the slide clean, and place it in a draining rack for the smear to air 
dry. 
10 Examine the smear microscopically, first with the 40x objective to check the staining 
and to see the distribution of material, and then with the oil immersion objective to 
report the bacteria and cells. 
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D. Biochemical testing procedures 
Identification of Gram negative bacteria: will be based on their test result with a series of 
biochemical tests. 
Procedure 
1. Prepare a suspension of the test organism with nutrient broth. 3-4 colony of test organism 
in 5 ml nutrient broth. 
2. A loop full of the bacterial suspension is inoculated in to indole, citrate agar, triple sugar 
iron agar, lysine decarboxylase agar, mannitol, urea agar and motility medium. 
3. Incubate at 35-37 Oc for 18-24 hours. 
4. Look for color change (turbidity for motility) of the medium 
5. Identify the test organism by considering the result of the six biochemical tests and their 
motility characteristics by comparing with the identification chart.  
E. Antimicrobial susceptibility testing 
1. Prepare a suspension of the test organism by emulsifying several colonies of the 
organism in a small volume of nutrient broth until it matches with a turbidity of 0.5 
McFarland standard 
2. Take a sample from the suspension with a sterile swab (squeeze the swab against the 
side of the test tube to remove the excess fluid). 
3. Spread the inoculums evenly over Muller-Hinton agar plate with the swab 
4. Using a sterile forceps or needle, place the antimicrobial disc on the inoculated plate 
5. Incubate the plate aerobically at 35-37oC for 18-24 hours 
6. Read the test after checking that the bacterial growth is neither heavy nor light. Measure 
the radius of the inhibition zone. 
7. Interpret the reaction of the test organism to each antibiotic used as sensitive, 
intermediate, or resistance as per the standard 
 Sensitive– zone of inhibition is wider or equal to the CLSI recommended 
zone size for each isolated strain 
Intermediate– If the zone of inhibition is within the intermediate range of 
CLSI guideline  
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Annex VI: Dummy Tables 
Table 1: Socio-demographic characteristics of HIV patients at the University of Gondar 
Hospital, 2017 
 
 
 
 
 
Variables  Frequency Percent P value 
Age in year <30  
 
  
30-44  
 
  
>44 
 
   
Sex  
 
Male 
 
 
 
  
Female 
 
 
 
  
Education 
 
Primary and below 
 
   
Secondary 
 
   
Collage/University 
 
   
Residence 
 
Urban  
 
  
Rural      
 
  
Occupation Farmer  
 
 
 
  
 Daily labourer 
 
 
 
  
 Merchant 
 
 
 
  
 House wife  
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Table 2: ESBL production among the Gram negative isolates on HIV patients at the 
University of Gondar Hospital, 2017 
Bacterial spcies Number of ESBL producer(%) Number of ESBL non producer(%) 
   
   
   
 
Table 3: Antibiotic susceptibility pattern of ESBL producing isolates on HIV patients at the 
University of Gondar Hospital, 2017 
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 Key:     S=Sensitive                    R=Resistance                      
              I =Intermediate 
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Table 4: Association of ESBL infection and risk factors on HIV patients at the University of 
Gondar Hospital, 2017 
 
Risk factors ESBL-PE  COR AOR(95% CI) p value 
Yes  No 
Previous antibiotic use Yes      
No      
Hospitalization 
 
Yes      
No      
Invasive procedure Yes      
No      
Intake of self prescribed 
antibiotics 
Yes      
No      
Oral contraceptive intake  Yes      
No      
Pregnancy Yes      
No      
CD4  count                       <500       
>500       
Previous history of UTI Yes      
No      
Cotrimoxazole prophylaxis 
treatment 
Yes      
No      
Adherence of cotrimoxazole Complete      
Incomplete      
ART  treatment Yes      
No      
 
WHO AIDS staging 
 
Stage I      
Stage II      
Stage III      
Stage IV      
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